Director Karen Drexler of ResMed Inc filed a statement of changes in beneficial ownership on November 20, 2026, disclosing an acquisition of ResMed common stock through a restricted stock unit award dated November 19, 2026.

Key Highlights

  • Reporting person: Karen Drexler, serving as a director of ResMed Inc (NYSE:RMD)
  • Transaction date: November 19, 2026, with the filing submitted November 20, 2026
  • Shares acquired: 1,109 shares of ResMed Common Stock at a price of $0, coded as an acquisition (A)
  • Security type: Restricted Stock Units (RSUs) that vest in full on the earlier of November 11, 2027, or the annual meeting of stockholders in the year following the grant date
  • Resulting ownership: 11,711 shares of ResMed Common Stock beneficially owned directly following the transaction

ResMed Director Karen Drexler's RSU Award on November 19, 2026

According to the filing, Karen Drexler, a director of ResMed Inc, received 1,109 shares of ResMed Common Stock in the form of Restricted Stock Units on November 19, 2026. The award was recorded at a price of $0 and is classified as an acquisition under Table I of the disclosure. ResMed Inc, listed on the New York Stock Exchange under the ticker RMD, develops and markets medical devices and software solutions focused on sleep and respiratory health, with its principal offices located at 9001 Spectrum Center Blvd, San Diego, California 92123.

The filing states that the RSUs "vest in full on the earlier of 11/11/2027, or the annual meeting of stockholders in the year following the grant date." Following the reported transaction, Drexler directly holds 11,711 shares of ResMed Common Stock in total. The transaction was filed by one reporting person, and the ownership form is listed as direct (D). No derivative securities were reported in Table II of the disclosure.

What Was Disclosed

The filing reports that ResMed director Karen Drexler was awarded 1,109 Restricted Stock Units on November 19, 2026, at no cost, bringing her total direct beneficial ownership of ResMed Common Stock to 11,711 shares. The RSUs vest no later than November 11, 2027.